People · Operator
Named in public records as an officer, director or promoter · active 2009–2021 · Biotechnology, Other, Other Health Care, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| NextCure, Inc. | — | Biotechnology | Series C | $129.9M | $113.9M | 2015 |
| Antiva Biosciences, Inc. | — | Biotechnology | Series B | $96.8M | $457.8M | 2015 |
| Trius Therapeutics Inc | — | Biotechnology | Series B | $49.3M | $1.2B | 2009 |
| Allylix Inc. | — | Other | Series B | $34.2M | $41.5M | 2014 |
| bioTheranostics, Inc. | — | Other Health Care | Series B | $20.0M | $443.1M | 2016 |
| Dauntless 1, Inc. | — | Pharmaceuticals | Series A | $15.0M | $247.8M | 2016 |
| Dauntless 2, Inc. | — | Pharmaceuticals | Series A | $6.1M | $187.5M | 2016 |
David Kabakoff at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Kabakoff on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Powell | 2 | 14 |
| Joel Martin | 2 | 5 |
| David P. Kabakoff | 2 | 2 |
| Wende Hutton | 1 | 16 |
| Risa Stack | 1 | 9 |
| Brian G. Atwood | 1 | 8 |
| Judith Li | 1 | 8 |
| Eric Bednarski | 1 | 7 |
| John Finn | 1 | 5 |
| Michael J Sullivan | 1 | 4 |
| Michael Yi | 1 | 4 |
| Theodore R. Schroeder | 1 | 4 |
| John Schmid | 1 | 4 |
| Nina S. Kjellson | 1 | 4 |
| Vinzenz Ploerer | 1 | 4 |
| Jeffrey Stein | 1 | 4 |
| Ron Meeusen | 1 | 4 |
| Michael Cannon | 1 | 4 |
| Elaine V. Jones | 1 | 3 |
| Paul Truex | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.